




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07D 253/06, A61K 31/53, C07D 403/10, 417/10		A1	(11) International Publication Number: WO 99/02504
			(43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/EP98/04192		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 July 1998 (02.07.98)			
(30) Priority Data: 97202117.4 10 July 1997 (10.07.97) EP			
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).			
(72) Inventors; and		Published With international search report.	
(75) Inventors/Applicants (for US only): FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). BOECKX, Gustaaf, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN WAUWE, Jean, Pierre, Frans [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DIELS, Gaston, Stanislas, Marcella [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).			

(54) Title: 6-AZAUACIL DERIVATIVES AS IL-5 INHIBITORS

(57) Abstract

The present invention is concerned with the use of compounds of formula (I): the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *p* represents 0, 1, 2 or 3; *q* represents 0, 1, 2, 3 or 4; *R*¹ represents hydrogen, C₁-alkyl, mono- or di(C₁-alkyl)amino, C₁-alkyloxy, mercapto, C₁-alkylthio, C₃-cycloalkyl, aryl or C₁-alkyl substituted with mono- or di(C₁-alkyl)-amino, C₁-alkyloxy, aryl or Het; *R*² represents cyano or a radical of formula -C(=X)-Y-R⁵; wherein X represents O or S; Y represents O, S, NR⁶ or a direct bond; *R*⁵ represents hydrogen; C₃-cycloalkyl; aryl or optionally substituted C₁-alkyl; and where Y is a direct bond, *R*⁵ may also be halo or Het; *R*³ and *R*⁴ each independently represents halo, haloC₁-alkyl, C₁-alkyl, hydroxy, C₁-alkyloxy, C₁-alkylcarbonyloxy, mercapto, C₁-alkylthio, C₁-alkylsulfonyl, C₁-alkylsulfinyl, haloC₁-alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁-alkyl)amino or (C₁-alkylcarbonyl)amino; aryl represents phenyl or substituted phenyl; and Het represents an optionally substituted heterocycle; in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases. The invention also relates to novel compounds, their preparation and compositions comprising them.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

6-AZAUACIL DERIVATIVES AS IL-5 INHIBITORS


5 The present invention concerns the use of IL-5 inhibiting 6-azauracil derivatives in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases. It further relates to certain novel 6-azauracil derivatives, to processes for their preparation and compositions comprising them.

10 Eosinophil influx, leading to subsequent tissue damage, is an important pathogenic event in bronchial asthma and allergic diseases. The cytokine interleukin-5 (IL-5), produced mainly by T lymphocytes as a glycoprotein, induces the differentiation of eosinophils in bone marrow and, primes eosinophils for activation in peripheral blood and sustains their survival in tissues. As such, IL-5 plays a critical role in the process of eosinophilic inflammation. Hence, the possibility that inhibitors of IL-5 production
15 would reduce the production, activation and/or survival of eosinophils provides a therapeutic approach to the treatment of bronchial asthma and allergic diseases such as, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, and also other eosinophil-dependent inflammatory diseases.

20 Steroids, which strongly inhibit IL-5 production *in vitro*, have long been used as the only drugs with remarkable efficacy for bronchial asthma and atopic dermatitis, but they cause various serious adverse reactions such as diabetes, hypertension and cataracts. Therefore, it would be desirable to find non-steroidal compounds having the ability to inhibit IL-5 production in human T-cells and which have little or no adverse
25 reactions.

US 4,631,278 discloses α -aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-benzeneacetonitriles and US 4,767,760 discloses 2-(substituted phenyl)-1,2,4-triazine-3,5(2*H*,4*H*)-diones, all having anti-protozoal activity, in particular, anti-coccidial
30 activity. Unexpectedly, the 6-azauracil derivatives of the present invention, including said art-known 1,2,4-triazinedione derivatives, prove to be potent inhibitors of the production of IL-5.

The present invention is concerned with the use of compounds of formula



the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein :

p represents an integer being 0, 1, 2, 3 or 4;

5 *q* represents an integer being 0, 1, 2, 3, 4 or 5;

*R*¹ represents hydrogen, C₁-6alkyl, mono-or di(C₁-6alkyl)aminoC₁-6alkyloxy, mercapto, C₁-6alkylthio, C₃-7cycloalkyl, aryl or C₁-6alkyl substituted with mono-or di(C₁-6alkyl)amino, C₁-6alkyloxy, aryl or Het;

*R*² represents cyano or a radical of formula -C(=X)-Y-*R*⁵; wherein

10 X represents O or S;

Y represents O, S, NR⁶ or a direct bond;

*R*⁵ represents hydrogen; C₁-6alkyl; C₃-7cycloalkyl; aryl or C₁-6alkyl substituted with aryl, hydroxy or Het; and where Y is a direct bond, *R*⁵ may also be halo or Het;

*R*⁶ represents hydrogen, C₁-6alkyl, C₁-6alkyloxy or arylC₁-6alkyl;

15 each *R*³ independently represents halo, haloC₁-6alkyl, C₁-6alkyl, hydroxy, C₁-6alkyloxy, C₁-6alkylcarbonyloxy, mercapto, C₁-6alkylthio, C₁-6alkylsulfonyl, C₁-6alkylsulfinyl, haloC₁-6alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁-6alkyl)amino or (C₁-6alkylcarbonyl)amino;

20 each *R*⁴ independently represents halo, haloC₁-6alkyl, C₁-6alkyl, hydroxy, C₁-6alkyloxy, C₁-6alkylcarbonyloxy, mercapto, C₁-6alkylthio, C₁-6alkylsulfonyl, C₁-6alkylsulfinyl, haloC₁-6alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁-6alkyl)amino or (C₁-6alkylcarbonyl)amino;


25 aryl represents phenyl or phenyl-substituted with one, two or three substituents selected from the group comprising halo, C₁-6alkyl, C₁-6alkyloxy, haloC₁-6alkyl, hydroxy, mercapto, C₁-6alkylthio, C₁-6alkylsulfonyl, C₁-6alkylsulfonyloxy, C₁-6alkylsulfinyl, haloC₁-6alkylsulfonyl, nitro, cyano, amino, mono- and di(C₁-6alkyl)amino and C₁-6alkylcarbonylamino; and

30 Het represents a heterocycle selected from pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, pyrazolyl, pyrazoliny, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazoliny, isoxazolyl, thiazolyl, thiazoliny, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl,


- isobenzofuranyl, benzthiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolyl, phthalazinyl, quinazolinyl, quinoxalinyl and thiazolopyridinyl; said heterocycles each independently may be substituted with one, two or three substituents selected from hydroxy, mercapto, C₁₋₄alkyl, C₁₋₄alkyloxy, cyano, amino, nitro, mono- or di(C₁₋₄alkyl)amino, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(aryl)amino, halo, haloC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, aryl, furanyl, thienyl, pyridinyl, piperidinyl, C₁₋₄alkylcarbonylpiperidinyl and C₁₋₄alkyl substituted with hydroxy, C₁₋₄alkyloxy, aryl, piperidinyl, amino, mono- or di(C₁₋₄alkyl)amino or C₃₋₇cycloalkyl;
- 10 in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases.

- The compounds of formula (I) are deemed novel, provided that the α -aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitriles published in US-4,631,278 and the 2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-diones published in US 4,767,760 are excluded therefrom.

Thus, the invention also concerns novel compounds of formula



- 20 the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *p*, *q*, R¹, R², R³ and R⁴ are as defined in the compounds of formula (I), provided that the following conditions apply to the variables R^{3a}, R^{3b}, R^{3c}, R^{4a}, R^{4b}, R^{4c}, R¹ and R² in the compounds with general structure :



- 25 a) if R^{3a}, R^{3b} are chloro; R^{4a} is 4-chloro; and R¹, R^{3c}, R^{4b} and R^{4c} are hydrogen; then R² is other than aminocarbonyl, carboxyl, chlorocarbonyl, 1-piperidinylcarbonyl, methoxycarbonyl, methylaminocarbonyl, 1-pyrrolidinylcarbonyl, 4-methyl-1-piperazinylcarbonyl, methylcarbonyl, NH₂-C(=S)-, phenylcarbonyl; and
- 30 b) if R^{3a} is chloro; R^{4a} is 4-chloro; and R¹, R^{3b}, R^{3c}, R^{4b} and R^{4c} are hydrogen; then R² is other than aminocarbonyl, carboxyl, NH₂-C(=S)-, chlorocarbonyl, methylamino-

carbonyl, (4-methylcarbonyl-1-piperazinyl)carbonyl, (4-phenylmethyl-1-piperazinyl)-carbonyl or methyloxycarbonyl; and

c) if the combination of R^1 , R^{3a} , R^{3b} , R^{3c} , R^{4a} , R^{4b} and R^{4c} is one of the following :

R^1	R^{3a}	R^{3b}	R^{3c}	R^{4a}	R^{4b}	R^{4c}
4-chlorophenyl	Cl	H	H	H	4-Cl	H
1-propyl	Cl	H	H	H	4-Cl	H
1-butyl	Cl	H	H	H	4-Cl	H
CH ₃	Cl	H	H	H	4-Cl	H
CH ₃	H	H	H	H	4-H	H
CH ₃	H	Cl	H	H	4-F	H
CH ₃	CF ₃	H	H	H	4-Cl	H
CH ₃	Cl	H	H	3-CF ₃	4-Cl	H
CH ₃	Cl	Cl	H	H	4-Cl	H
CH ₃	Cl	CH ₃	H	H	4-Cl	H
CH ₃	F	H	H	H	4-F	H
H	Cl	CH ₃	H	H	4-Cl	H
H	Cl	H	H	H	4-F	H
H	Cl	H	H	H	4-CH ₃	H
H	Cl	Cl	H	H	4-F	H
H	Cl	CH ₃	H	H	4-F	H
H	CH ₃	CH ₃	H	H	4-F	H
H	CH ₃	CH ₃	H	H	4-Cl	H
H	Cl	Cl	H	H	4-Cl	H
H	Cl	H	H	H	4-Cl	H
H	Cl	H	H	2-Cl	4-Cl	H
H	Cl	H	H	2-Cl	4-Cl	6-Cl
H	Cl	H	H	H	4-Br	H
H	Cl	Cl	H	H	4-Br	H
H	Cl	Cl	H	H	4-CH ₃ C(=O)O	H
H	Cl	Cl	H	H	4-OH	H
H	OH	H	H	H	4-Cl	H
H	Cl	H	H	H	4-CH ₃ S	H
H	Cl	Cl	H	H	4-CH ₃ S	H
H	CH ₃	CH ₃	H	H	4-CH ₃ S	H
H	Cl	H	H	3-CH ₃	4-CH ₃ S	H
H	Cl	Cl	H	3-CH ₃	4-CH ₃ S	H
H	Cl	H	H	H	4-CH ₃ SO	H
H	Cl	Cl	H	H	4-CH ₃ SO	H
H	Cl	H	H	H	4-CH ₃ S(O) ₂	H
H	Cl	Cl	H	H	4-CH ₃ S(O) ₂	H

R ¹	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}	R ^{4c}
H	Cl	H	H	H	4-SH	H
H	Cl	Cl	H	H	4-SH	H
CH ₃	Cl	H	CH ₃	4-Cl	H	H
H	H	H	OCH ₃	4-Cl	H	H

then R² is other than cyano.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₃₋₇cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; C₁₋₆alkyl is meant to include C₁₋₄alkyl and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like; haloC₁₋₆alkyl is defined as polyhalosubstituted C₁₋₆alkyl, in particular C₁₋₆alkyl substituted with 1 to 6 halogen atoms, more in particular difluoro- or trifluoromethyl.

Het is meant to include all the possible isomeric forms of the heterocycles mentioned in the definition of Het, for instance, pyrrolyl includes 2H-pyrrolyl; triazolyl includes 1,2,4-triazolyl and 1,3,4-triazolyl; oxadiazolyl includes 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl; thiadiazolyl includes 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl and 1,3,4-thiadiazolyl; pyranlyl includes 2H-pyranlyl and 4H-pyranlyl; thiazolopyridinyl includes thiazolo[5,4-b]pyridinyl, thiazolo[5,4-c]pyridinyl, thiazolo[5,4-d]pyridinyl and thiazolo[5,4-e]pyridinyl.

The heterocycles represented by Het may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heterocycle is imidazolyl, it may be a 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl; when it is triazolyl, it may be 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,3,4-triazol-1-yl and 1,3,4-triazol-2-yl; when it is benzthiazolyl, it may be 2-benzthiazolyl, 4-benzthiazolyl, 5-benzthiazolyl, 6-benzthiazolyl and 7-benzthiazolyl; when it is thiazolopyridinyl, it may be thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-b]pyridin-4-yl, thiazolo[5,4-b]pyridin-5-yl, thiazolo[5,4-b]pyridin-6-yl, thiazolo[5,4-c]pyridin-2-yl, thiazolo[5,4-c]pyridin-4-yl, thiazolo[5,4-c]pyridin-5-yl, thiazolo[5,4-c]pyridin-7-yl, thiazolo[5,4-d]pyridin-2-yl, thiazolo[5,4-d]pyridin-4-yl, thiazolo[5,4-d]pyridin-6-yl, thiazolo[5,4-d]pyridin-7-yl, thiazolo[5,4-e]pyridin-2-yl, thiazolo[5,4-e]pyridin-5-yl, thiazolo[5,4-e]pyridin-6-yl and

thiazolo[5,4-e]pyridin-7-yl.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.


The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms in which the compounds of formula (I) can exist. Unless

otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration, used herein in accordance with Chemical Abstracts nomenclature. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.

The compounds of formula (I) and some of the intermediates in the present invention contain one or more asymmetric carbon atoms. The pure and mixed stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of the present invention.

Whenever used hereinafter, the term "compounds of formula (I)" is meant to also include their *N*-oxide forms, their pharmaceutically acceptable addition salts, and their stereochemically isomeric forms.

The numbering of the phenyl ring bearing substituent R^4 is given hereinbelow and is used herein as such when indicating the position of the R^4 substituents on said phenyl ring, unless otherwise indicated.



The carbon atom bearing the two phenyl rings and the R^1 and R^2 substituents will be referred herein as the central chiral carbon atom.

A suitable subgroup consists of those compounds of formula (I) or (I') wherein Het is other than pyrrolidinyl.

A special group of compounds are those compounds of formula (I) or (I') wherein R^2 is a radical of formula $-C(=X)-Y-R^5$ wherein Y is a direct bond and R^5 is Het.

Another special group of compounds are those compounds of formula (I) or (I') wherein R^1 is mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio or C_{1-6} alkyl substituted with mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxy or Het.

An interesting group of compounds are those compounds of formula (I) or (I') wherein

the 6-azauracil moiety is connected to the phenyl ring in the para or meta position relative to the central chiral carbon atom, particularly in the para position.

5 Another interesting group of compounds are those compounds of formula (I) or (I') wherein R^2 is cyano.

10 Still another interesting group of compounds are those compounds of formula (I) or (I') wherein R^2 is a radical of formula $-C(=X)-Y-R^5$ wherein R^5 is hydrogen, C_{1-6} alkyl or aryl while Y is O, S or NR^6 wherein R^6 is hydrogen or C_{1-6} alkyloxy; or R^5 is aryl, C_{1-6} alkyl, halo, Het or C_{1-6} alkyl substituted with aryl while Y is a direct bond. Suitably, Het is optionally substituted piperazinyl, imidazolyl, thiazolyl or benzothiazolyl.

15 Yet another interesting group of compounds are those compounds of formula (I) or (I') wherein R^1 is hydrogen, aryl, C_{1-6} alkyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkyl or Het C_{1-6} alkyl.

20 Particular compounds are those compounds of formula (I) or (I') wherein R^3 and R^4 each independently are halo, halo C_{1-6} alkyl, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyl-carbonyloxy or aryl, more in particular, bromo, chloro, fluoro, trifluoromethyl, methyl, hydroxy, methoxy, methylcarbonyloxy or phenyl.

Other particular compounds are those compounds of formula (I) or (I') wherein p is 0, 1 or 2, and q is 0, 1, 2 or 3, more in particular, p and q each independently are 1 or 2.

25 Preferred compounds are those compounds of formula (I) or (I') wherein q is 1 or 2 and one R^4 substituent, preferably selected from chloro, fluoro, methyl, hydroxy, methoxy, methylcarbonyloxy and phenyl, is in the 4 position.

30 Other preferred compounds are those compounds of formula (I) or (I') wherein p is 1 or 2 and the one or two R^3 substituents, preferably selected from bromo, chloro, methyl, methoxy or trifluoromethyl, are in the ortho position relative to the central chiral carbon atom.


35 More preferred compounds are those compounds of formula (I) or (I') wherein the 6-azauracil moiety is in the para position relative to the central chiral carbon atom; p is 1 or 2 and one R^3 substituent is chloro positioned ortho relative to the central chiral carbon atom; q is 1 or 2 and one R^4 substituent is chloro in the 4 position.

Particularly preferred compounds are those compounds as described hereinabove as

more preferred compounds wherein R^2 is cyano or a radical of formula $-C(=X)-Y-R^5$ wherein Y is a direct bond.


The compounds of the present invention can generally be prepared as described in
 5 US-4,631,278 and US-4,767,760.

In particular, the compounds of formula (I') can be prepared by cyclizing an intermediate of formula (II) and eliminating the group E from the thus obtained dione of formula (III).




A suitable way of eliminating group E, which is for example a carboxyl group, may be reacting intermediate of formula (III) with mercaptoacetic acid or a functional derivative thereof.

15 The compounds of formula (I') may also be prepared by eliminating the protective group P in the intermediates of formula (IV).




A suitable way of eliminating group P, which is for example a alkyloxyalkyloxyalkyl moiety, may be reacting intermediate of formula (IV) with an acid or an acid mixture
 20 such as hydrochloric acid, acetic acid or a mixture thereof. Alternatively, the protective group P may be removed by reacting an intermediate of formula (IV) with a suitable reagent such as, for example, boron tribromide, in a reaction-inert solvent such as, for example, dichloromethane.

25 The compounds of formula (I') wherein R^2 is cyano, said compounds being represented by formula (I'-a), can be prepared by converting the hydroxyl function of an intermediate of formula (V) into a suitable leaving group W such as, for example, a halogen or a sulfonyloxy group, and subsequently converting said leaving group W in the thus formed intermediate of formula (VI) into a nitrile function.




The compounds of formula (I') wherein R^1 is hydrogen and R^2 is cyano, said compounds being represented by formula (I'-a-1), can be prepared by reacting the carbonyl group in the intermediates of formula (VII) with a suitable reagent such as, for example, 1-[(isocyanomethyl)sulfonyl]-4-methylbenzene or a functional derivative thereof.



The compounds of formula (I) can be converted into each other following art-known procedures of functional group transformation and are described in US 4,767,760,

Some interesting group transformation reactions described therein are mentioned hereinafter.

In order to simplify the structural representation of the compounds of formula (I'), the group




will hereinafter be represented by the symbol D.

The compounds of formula (I'-a) may be partially or completely hydrolyzed, thus

yielding compounds of formula (I') wherein R^2 is an aminocarbonyl or a carboxyl group, the former being represented by formula (I'-f), the latter by (I'-b). The compounds of formula (I'-f) can further be hydrolyzed to compounds of formula (I'-b).

- 5 The compounds of formula (I'-a) may also be converted to compounds of formula (I'-g) wherein R^2 is an aminothioxomethyl group.

- The acids of formula (I'-b) can be converted to the corresponding acylhalides of formula (I'-c). Said acylhalides of formula (I'-c) can further be derivatized using
 10 $\text{HN}(\text{R}^5)(\text{R}^6)$ to the corresponding amides of formula (I'-d) which in turn may further be reacted to a heteroaryl ketone of formula (I'-e) using a suitable metal alkyl such as, for example, butyl lithium, in a reaction-inert solvents such as, for example, tetrahydrofuran, hexane, diethylether or a mixture thereof. The latter reaction may conveniently be performed under an inert atmosphere such as, for example, oxygen-free nitrogen, and at a low reaction temperature, preferably at about -70°C . The acylhalides of
 15 formula (I'-c) can also be reacted with a Grignard reagent, e.g. RMgX , wherein X is a suitable counter ion such as a halogen, and R is C_{1-7} cycloalkyl or C_{1-6} alkyl optionally substituted with aryl or Het, thus obtaining intermediates of formula (I'-h).



- 20 In addition, the compounds of formula (I') may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali

- metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid,
- 5 alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
- 10 Pure stereochemically isomeric forms of the compounds of formula (I') may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g. counter-current distribution, liquid chromatography and the like.
- 15 The compounds of formula (I') as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I') which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid respectively with a
- 20 suitable chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I') involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from
- 25 the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- 30 An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
- 35 A number of intermediates and starting materials in the foregoing preparations are commercially available or are known compounds which may be prepared according to art-known methodologies of preparing said or similar intermediates. In particular, the preparation of the intermediates of formula (II), (IV), (V) and (VII) are described in

US-4,631,278, US-4,767,760, US-3,883,527 and Carroll et al. in J. Med. Chem. 1983, 26, 96-100.

- IL-5, also known as eosinophil differentiating factor (EDF) or eosinophil colony stimulating factor (Eo-CSF), is a major survival and differentiation factor for eosinophils and basophils and therefore thought to be a key player in eosinophil infiltration into tissues. There is ample evidence that eosinophil influx is an important pathogenic event in bronchial asthma and allergic diseases such as, cheilitis, irritable bowel disease, eczema, urticaria, vasculitis, vulvitis, winterfeet, atopic dermatitis, pollinosis, allergic rhinitis and allergic conjunctivitis; and other inflammatory diseases, such as eosinophilic syndrome, allergic angitis, eosinophilic fasciitis, eosinophilic pneumonia, PIE syndrome, idiopathic eosinophilia, eosinophilic myalgia, Crohn's disease, ulcerative colitis and the like diseases.
- The present compounds also inhibit the production of other chemokines such as monocyte chemotactic protein-1 and -3 (MCP-1 and MCP-3). MCP-1 is known to attract both T-cells, in which IL-5 production mainly occurs, and monocytes, which are known to act synergetically with eosinophils (Carr et al., 1994, Immunology, 91, 3652-3656). MCP-3 also plays a primary role in allergic inflammation as it is known to mobilize and activate basophil and eosinophil leukocytes (Baggiolini et al., 1994, Immunology Today, 15(3), 127-133).

The present compounds have no or little effect on the production of other chemokines such as IL-1, IL-2, IL-3, IL-4, IL-6, IL-10, γ -interferon (IFN- γ) and granulocyte-macrophage colony stimulating factor (GM-CSF) indicating that the present IL-5 inhibitors do not act as broad-spectrum immunosuppressives.

The selective chemokine-inhibitory effect of the present compounds can be demonstrated by *in vitro* chemokine measurements in human blood of which the test results for IL-5 are presented in the experimental part hereinafter. *In vivo* observations such as the inhibition of eosinophilia in mouse ear, the inhibition of blood eosinophilia in the *Ascaris* mouse model; the reduction of serum IL-5 protein production and splenic IL-5 mRNA expression induced by anti-CD3 antibody in mice and the inhibition of allergen- or Sephadex-induced pulmonary influx of eosinophils in guinea-pig are indicative for the usefulness of the present compounds in the treatment of eosinophil-dependent inflammatory diseases.

The present inhibitors of IL-5 production are orally active compounds.

In view of the above pharmacological properties, the present compounds can be used in the manufacture of a medicament for treating eosinophil-dependent inflammatory diseases as mentioned hereinabove, in particular bronchial asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. The present invention also involves two groups of novel compounds for use as a medicine. One of said groups consists of those compounds of formula (I') wherein R¹ is mono-or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, mercapto, C₁₋₆alkylthio or C₁₋₆alkyl substituted with mono-or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxy or Het, the other group consists of those compounds of formula (I') wherein R² is a radical of formula -C(=X)-Y-R⁵ wherein Y is a direct bond and R⁵ is Het.

In view of the utility of the compounds of formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from eosinophil-dependent inflammatory diseases, in particular bronchial asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. Said method comprises the systemic or topical administration of an effective amount of a compound of formula (I), a N-oxide form, a pharmaceutically acceptable addition salt or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.

The present invention also provides compositions for treating eosinophil-dependent inflammatory diseases comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent together with instructions for the use thereof for the treatment of an eosinophil-dependent inflammatory disease.

In particular, the present invention provides compositions for treating eosinophil-dependent inflammatory diseases comprising a therapeutically effective amount of a compound of formula (I') wherein R² is a radical of formula -C(=X)-Y-R⁵ wherein Y is a direct bond and R⁵ is Het or a compound of formula (I') wherein R¹ is mono-or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, mercapto, C₁₋₆alkylthio or C₁₋₆alkyl substituted with mono-or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxy or Het, and a pharmaceutically acceptable carrier or diluent.

To prepare the aforementioned pharmaceutical compositions, a therapeutically effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous, or parenteral administration; or topical administration such as via

inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. Application of said compositions may be by aerosol, e.g. with a propellant such as nitrogen, carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular, semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity

of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and
5 segregated multiples thereof.

Preferred compositions are those compositions containing a novel compound of formula (I') wherein R^2 is a radical of formula $-C(=X)-Y-R^5$ wherein Y is a direct bond and R^5 is Het, or a novel compound of formula (I') wherein R^1 is mono-or di(C_{1-6} alkyl)amino-
10 C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio or C_{1-6} alkyl substituted with mono-or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxy or Het, and are in dosage unit form, comprising per dosage unit an effective quantity of active ingredient in admixture with suitable carriers.

In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α -, β - or γ -cyclo-
15 dextrins or their derivatives. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions. In the preparation of aqueous compositions, addition salts of the subject compounds are obviously more suitable due to their increased water solubility.

Appropriate cyclodextrins are α -, β -, γ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C_{1-6} alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated β -CD; hydroxy C_{1-6} alkyl, particularly hydroxyethyl, hydroxy-
25 propyl or hydroxybutyl; carboxy C_{1-6} alkyl, particularly carboxymethyl or carboxyethyl; C_{1-6} alkylcarbonyl, particularly acetyl; C_{1-6} alkyloxycarbonyl C_{1-6} alkyl or carboxy- C_{1-6} alkyloxy C_{1-6} alkyl, particularly carboxymethoxypropyl or carboxyethoxypropyl; C_{1-6} alkylcarbonyloxy C_{1-6} alkyl, particularly 2-acetyloxypropyl.

Especially noteworthy as complexants and/or solubilizers are β -CD, randomly
30 methylated β -CD, 2,6-dimethyl- β -CD, 2-hydroxyethyl- β -CD, 2-hydroxyethyl- γ -CD, 2-hydroxypropyl- γ -CD and (2-carboxymethoxy)propyl- β -CD, and in particular 2-hydroxypropyl- β -CD (2-HP- β -CD).

The term mixed ether denotes cyclodextrin derivatives wherein at least two
35 cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxy-propyl and hydroxyethyl.

Due to their high degree of selectivity as IL-5 inhibitors, the compounds of formula (I)

as defined above, are also useful to mark or identify receptors. To this purpose, the compounds of the present invention need to be labelled, in particular by replacing, partially or completely, one or more atoms in the molecule by their radioactive isotopes. Examples of interesting labelled compounds are those compounds having at least one halo which is a radioactive isotope of iodine, bromine or fluorine; or those compounds having at least one ^{11}C -atom or tritium atom.

One particular group consists of those compounds of formula (I) wherein R^3 and/or R^4 are a radioactive halogen atom. In principle, any compound of formula (I) containing a halogen atom is prone for radiolabelling by replacing the halogen atom by a suitable isotope. Suitable halogen radioisotopes to this purpose are radioactive iodides, e.g. ^{122}I , ^{123}I , ^{125}I , ^{131}I ; radioactive bromides, e.g. ^{75}Br , ^{76}Br , ^{77}Br and ^{82}Br , and radioactive fluorides, e.g. ^{18}F . The introduction of a radioactive halogen atom can be performed by a suitable exchange reaction or by using any one of the procedures as described hereinabove to prepare halogen derivatives of formula (I).

Another interesting form of radiolabelling is by substituting a carbon atom by a ^{11}C -atom or the substitution of a hydrogen atom by a tritium atom.

Hence, said radiolabelled compounds of formula (I) can be used in a process of specifically marking receptor sites in biological material. Said process comprises the steps of (a) radiolabelling a compound of formula (I), (b) administering this radiolabelled compound to biological material and subsequently (c) detecting the emissions from the radiolabelled compound. The term biological material is meant to comprise every kind of material which has a biological origin. More in particular this term refers to tissue samples, plasma or body fluids but also to animals, specially warm-blooded animals, or parts of animals such as organs.

The radiolabelled compounds of formula (I) are also useful as agents for screening whether a test compound has the ability to occupy or bind to a particular receptor site. The degree to which a test compound will displace a compound of formula (I) from such a particular receptor site will show the test compound ability as either an agonist, an antagonist or a mixed agonist/antagonist of said receptor.

When used in *in vivo* assays, the radiolabelled compounds are administered in an appropriate composition to an animal and the location of said radiolabelled compounds is detected using imaging techniques, such as, for instance, Single Photon Emission Computerized Tomography (SPECT) or Positron Emission Tomography (PET) and the like. In this manner the distribution of the particular receptor sites throughout the body can be detected and organs containing said receptor sites can be visualized by the

imaging techniques mentioned hereinabove. This process of imaging an organ by administering a radiolabelled compound of formula (I) and detecting the emissions from the radioactive compound also constitutes a part of the present invention.

- 5 A suitable therapeutically effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, in particular from 0.05 mg/kg to 10 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.

10 Experimental part

A. Preparation of the intermediate compounds

Hereinafter, "THF" stands for tetrahydrofuran, "RT" stands for room temperature, "DIPE" stands for diisopropylether, "EtOAc" stands for ethylacetate and "DMF" stands for *N,N*-dimethylformamide.

15 Example A.1

- a) A solution of 4-chloro-3-(trifluoromethyl)benzeneacetonitrile (0.114 mol) in THF (100ml) was added dropwise at RT to a solution of 1,2,3-trichloro-5-nitrobenzene (0.114 mol) and *N,N,N*-triethylbenzenemethanaminium chloride (3g) in NaOH (150ml) and THF (100ml). The mixture was stirred at RT for 2 hours, then poured out
20 on ice, acidified with a concentrated HCl solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 40.4g (86.5%) of (±)-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)phenyl]-4-nitrobenzeneacetonitrile (interm. 1).
- 25 b) A mixture of (3,4-dichlorophenyl)acetonitrile (0.149 mol) in DMF (100ml) was stirred at 0°C under N₂ flow. Sodium hydride (0.223 mol) was added portionwise. The mixture was stirred at 0°C under N₂ flow for 1 hour. A mixture of, 2-methoxy-1,3-dimethyl-5-nitrobenzene (0.149 mol) in DMF (100ml) was added dropwise at 0°C under N₂ flow. The mixture was stirred at RT for 6 hours, then cooled, hydrolyzed with H₂O
30 and with HCl 3N and extracted with EtOAc. The organic layer was separated, washed several times with H₂O, dried, filtered and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 43.4g (87%) of (±)-α-(3,4-dichlorophenyl)-2,6-dimethyl-4-nitrobenzeneacetonitrile (interm. 48).
- 35 c) A solution of intermediate 1 (0.0466 mol), iodomethane (0.0606 mol), KOH (0.1864 mol) and *N,N,N*-triethylbenzenemethanaminium chloride (0.0466 mol) in toluene (200ml) was stirred at 50°C for 2 hours. The mixture was poured out into water, acidified with HCl (3N) and extracted with CH₂Cl₂. The organic layer was

separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 90/10). The pure fractions were collected and the solvent was evaporated, yielding 11g (55%) of
5 (±)-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)phenyl]-α-methyl-4-nitrobenzene-acetonitrile (interm. 2)

Example A.2

- a) A mixture of intermediate 2 (0.0259 mol) in methanol (200ml) was hydrogenated at 40°C overnight with platinum-on-activated carbon (1%; 1g) as a catalyst in the presence of thiophene (10% in ethanol; 1ml). After uptake of hydrogen, the catalyst
10 was filtered through celite, washed with CH₃OH and the filtrate was evaporated, yielding 10g (98%) of (±)-4-amino-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)-phenyl]-α-methylbenzeneacetonitrile (interm. 3).
- b) A mixture of intermediate 1 (0.138 mol) in methanol (300ml) was hydrogenated at RT under a 3 bar pressure for 1 hour with Raney Nickel (50g) as a catalyst in the
15 presence of a 10% thiophene solution in ethanol (5ml). After uptake of hydrogen, the catalyst was filtered through celite, washed with CH₃OH and CH₂Cl₂ and the filtrate was evaporated, yielding 49.5g (94%) of (±)-4-amino-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)phenyl]benzeneacetonitrile (interm. 46).
- c) A solution of 15 % TiCl₃ in water (0.13 mol) was added dropwise at RT to a solution
20 of (±)-2,6-dibromo-α-(4-chlorophenyl)-4-nitrobenzeneacetonitrile (0.026 mol) in THF (200ml). The mixture was stirred at RT for 2 hours, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, washed with H₂O and with K₂CO₃ 10%, dried, filtered and the solvent was evaporated. A part of this residue (2g) was
crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 1.3g
25 (±)-4-amino-2,6-dibromo-α-(4-chlorophenyl)benzeneacetonitrile (interm. 47).

Example A.3


- a) A solution of sodium nitrite (0.0243 mol) in water (10ml) was added dropwise at 5°C to a solution of intermediate 3 (0.0243 mol) in acetic acid (75ml) and concentrated HCl (20ml). The mixture was stirred at 0°C for 35 minutes and then added dropwise to
30 a solution of ethyl (cyanoacetyl)carbamate (0.0326 mol) and sodium acetate (112g) in ice water (1300ml). The mixture was stirred at 0°C for 45 minutes. The precipitate was filtered off, washed with water and taken up in CH₂Cl₂. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated, yielding 15.2 g (±)-ethyl 2-cyano-2-[[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-cyanoethyl]phenyl]hydrazono]-1-oxoethylcarbamate (interm. 4)
- b) A mixture of intermediate 4 (0.0271 mol) and potassium acetate (0.0285 mol) in

acetic acid (150ml) was stirred and refluxed for 3 hours and then poured out on ice. The precipitate was filtered off, washed with water and taken up in EtOAc. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated, yielding 12g (86%) of (\pm)-2-[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-cyanoethyl]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile (interm. 5).

- 5 c) A mixture of intermediate 5 (0.0223 mol) in HCl (40ml) and acetic acid (150ml) was stirred and refluxed for 3 hours and then poured out into ice water. The precipitate was filtered off, taken up in CH₂Cl₂ and CH₃OH, washed with water, dried, filtered and the solvent was evaporated, yielding 11.4g (96%) of (\pm)-2-[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-cyanoethyl]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carboxylic acid (interm. 6).

The following intermediates were prepared according to the procedures described in example A.3.

15 Table 1



Interm. No.	R ¹	R ²	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}	R ^{4c}	R ^{4d}
7	CH ₃	CN	Cl	H	H	H	Cl	Cl	H
8	CH ₃	CN	Cl	H	H	H	OCH ₃	OCH ₃	H
9	CH ₃	CN	Cl	H	H	H	OCH ₃	H	H
10	CH ₃	CN	Cl	H	H	H	Cl	OCH ₃	H
11	CH ₃	CN	Cl	H	CH ₃	H	Cl	CF ₃	H
12	CH ₃	CN	Cl	H	H	H	Cl	OCH ₃	H
13	CH ₃	CN	OCH ₃	H	H	H	Cl	CF ₃	H
14	CH ₃	CN	Cl	H	H	OCH ₃	OCH ₃	OCH ₃	H
15	CH ₃	CN	Cl	Cl	H	H	Cl	Cl	H
16	CH ₃	CN	Cl	H	H	H	Cl	CH ₃	H
17	CH ₃	CN	Cl	H	H	H	CH ₃	OCH ₃	H
18	CH ₃	CN	Cl	H	H	H	Cl	H	Cl
19	CH ₃	CN	H	H	H	H	Cl	H	Cl
20	CH ₃	CN	CH ₃	H	H	CF ₃	Cl	H	H
21	CH ₃	CN	Cl	H	H	H	phenyl	H	H
33	H	CN	CH ₃	CH ₃	H	H	Cl	Cl	H

Interm. No.	R ¹	R ²	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}	R ^{4c}	R ^{4d}
34	H	CN	Cl	Cl	H	H	Cl	CH ₃	H
35	CH ₃	CN	Cl	Cl	H	H	Cl	F	H
36	H	CN	Cl	Cl	H	H	Cl	OCH ₃	H
37	H	CN	Br	Br	H	H	Cl	H	H
38	CH ₃	C(=O)OC ₂ H ₅	Cl	Cl	H	H	Cl	H	H

Example A.4

- 5 a) A mixture of (±)-4-chloro-α-[2-chloro-3-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)phenyl]-3-(trifluoromethyl)benzeneacetonitrile (0.00542 mol), 1-(chloromethoxy)-2-methoxyethane (0.006 mol) and triethylamine (0.0065 mol) in THF (15ml) was stirred at RT for 2 hours. The mixture was poured out into water and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 3.4 g of (±)-4-chloro-α-[2-chloro-3-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]phenyl]-3-(trifluoromethyl)benzeneacetonitrile (interm. 22). (±)-2-chloro-α-(4-chlorophenyl)-4-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]benzeneacetonitrile was prepared in an analogous way (interm. 39).
- 10 b) 2-methyl-2-propanol, potassium salt (0.0193 mol) was added portionwise at 0°C under N₂ flow to a solution of intermediate 22 (0.00642 mol) and iodomethane (0.0321 mol) in DMF (10ml). The mixture was stirred at 0°C for 2 hours, then poured out into ice water and extracted with diethyl ether. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 50/50 to 35/65). The pure fractions were collected and the solvent was evaporated, yielding 2.07 g (60%) of (±)-4-chloro-α-[2-chloro-3-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]phenyl]-α-methyl-3-(trifluoromethyl)-benzeneacetonitrile (interm. 23).
- 15 (±)-4-chloro-α-[2-chloro-5-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]phenyl]-α-methyl-3-(trifluoromethyl)benzeneacetonitrile was prepared in an analogous way (interm. 24).

25 Example A.5

- a) A solution of 4-bromo-1-chloro-2-(trifluoromethyl)benzene (0.165 mol) in THF (30ml) was added dropwise under N₂ flow to a suspension of Mg (0.181 mol) and a crystal of I₂ in THF (20 ml). The mixture was stirred at 30-35°C for 2.5 hours and then cooled to 10°C. The mixture was added dropwise at 5°C under N₂ flow to a solution of *N*-(2-chloro-3-formylphenyl)acetamide (0.0788 mol) in THF (500ml). The
- 30

- mixture was stirred at RT for 3 hours, poured out into ice and NH_4Cl , and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98.5/1.5). The pure fractions were collected and the solvent was evaporated, yielding 22.2g (74%) of (\pm)-*N*-[2-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]hydroxymethyl]phenyl]acetamide (interm. 25).
- 5 b) A mixture of intermediate 25 (0.0587 mol) and manganese(IV) oxide (0.587 mol) in CH_2Cl_2 (400ml) was stirred at RT for 24 hours and filtered over celite. The solvent was evaporated, yielding 19.21g (87%) of *N*-[2-chloro-3-[4-chloro-3-(trifluoromethyl)benzoyl]phenyl]acetamide (interm. 26).
- 10 c) A mixture of intermediate 26 (0.0511 mol) in HCl (6N; 200ml) was stirred and refluxed for 5 hours. The mixture was cooled, poured into ice, basified with NH_4OH and extracted with CH_2Cl_2 . The organic layer was dried, filtered and the solvent was evaporated, yielding 17.1g (100%) of (3-amino-2-chlorophenyl)[4-chloro-3-(trifluoromethyl)phenyl]methanone (interm. 27).
- 15 d) 2-[2-chloro-3-[4-chloro-3-(trifluoromethyl)benzoyl]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carboxylic acid was prepared according to the procedures described in example A2.a), A2.b) and A2.c) (interm. 28).
- e) A mixture of intermediate 28 (0.0207 mol) in mercaptoacetic acid (10ml) was heated at 160°C for 3 hours. The solution was cooled and poured on ice. EtOAc was added and the mixture was basified with NaHCO_3 . The organic layer was separated, dried, filtered and the solvent was evaporated. 0.8g of the residue was crystallized from 2-propanol/DIPE. The precipitate was filtered off and dried, yielding 0.5g (93%) of 2-[2-chloro-3-[4-chloro-3-(trifluoromethyl)benzoyl]phenyl]-1,2,4-triazine-3,5(2*H*,4*H*)-dione (interm. 29).
- 25 2-[4-chloro-3-[4-chloro-3-(trifluoromethyl)benzoyl]phenyl]-1,2,4-triazine-3,5(2*H*,4*H*)-dione was prepared according to the procedures described in example A5.a) through A5.e) (interm. 30).

Example A.6

- 30 a) A mixture of 2-[4-(4-chlorobenzoyl)phenyl]-1,2,4-triazine-3,5-(2*H*,4*H*)-dione (0.05 mol), ethanol (150 ml), water (150 ml) and NaOH (50%; 10 ml) was stirred at 10°C. A mixture of NaBH_4 (0.05 mol), water (50 ml) and NaOH (50%; 2 ml) was added dropwise during 15 minutes. After stirring for 3 hours, 300 ml ice was added. The mixture was acidified with concentrated HCl. The product was extracted with
- 35 CHCl_3 , yielding 5.8 g of 2-[4-[(4-chlorophenyl)hydroxymethyl]phenyl]-1,2,4-triazine-3,5-(2*H*,4*H*)-dione (interm. 31). The organic layer was dried, filtered and evaporated. The residue was crystallized with 2-propanol. The product was filtered off, washed

with 2,2'-oxybispropane and dried, yielding a second fraction of 5.5 g of intermediate 31.

- b) A mixture of intermediate 31 (0.053 mol), thionylchloride (50 ml) and CHCl_3 (200 ml) was stirred and refluxed for 2 hours. The solvent was evaporated. After the addition of toluene, the solvent was evaporated again, yielding 18.4 g of 2-[4-[chloro-(4-chlorophenyl)methyl]phenyl]-1,2,4-triazine-3,5-(2*H*,4*H*)-dione (interm. 32).

Example A.7

- a) NaH (0.042 mol; 80 % in oil) was added portionwise at 10°C under N_2 flow to a solution of intermediate 39 (0.0325 mol) in DMF (90ml). The mixture was stirred for 15 minutes. A solution of 1-bromo-3-chloro-propane (0.065 mol) in DMF (20ml) was added dropwise. The mixture was stirred at RT for 24 hours. H_2O (250ml) was added. The mixture was filtered over celite, washed with H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ 85/15). The pure fractions were collected and the solvent was evaporated, yielding 7.5g (43%) of (\pm)-2-chloro- α -(4-chlorophenyl)- α -(3-chloropropyl)-4-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]benzeneacetonitrile (interm. 40).
- b) A mixture of intermediate 40 (0.0132 mol), dimethylamine (0.066 mol) and potassium carbonate (0.066 mol) in acetonitrile (100ml) was stirred and refluxed for 12 hours and then allowed to cool to RT. H_2O was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97.5/2.5/0.5). The pure fractions were collected and the solvent was evaporated, yielding 2.5g (35%) of (\pm)-2-chloro- α -(4-chlorophenyl)-4-[4,5-dihydro-4-[(2-methoxyethoxy)methyl]-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl]- α -[3-(dimethylamino)propyl]-benzeneacetonitrile (interm. 41).

Example A.8

- a) A mixture of (\pm)-4-amino-2,6-dichloro- α -[4-chloro-3-(trifluoromethyl)phenyl]- α -methylbenzeneacetonitrile (0.08 mol) in acetic acid (250 ml) and concentrated chloric acid (0.24 mol) was stirred at $\pm 10^\circ\text{C}$. A solution of sodium nitrite (0.08 mol) in water (15 ml) was added dropwise over 30 minutes at $\pm 10^\circ\text{C}$. The mixture was stirred for one hour. Sodium acetate (0.24 mol) and carbamic acid, (1,3-dioxo-1,3-propanediyl)-bis-, diethyl ester (0.088 mol) were added in one portion. The resulting reaction mixture was stirred for 2 hours at RT. The mixture was poured out into ice-water, and the resulting precipitate was filtered off, washed with water, then dissolved in CH_2Cl_2 . The organic solution was dried, filtered and the solvent evaporated. A sample of the

residue (2 g) was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 99/1). The desired fractions were collected and the solvent was evaporated. The residue was stirred in DIPE, filtered off, washed and dried, yielding 0.95 g of diethyl (A)-N,N'-[2-[[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-

5 cyanoethyl]phenyl]hydrazono]-1,3-dioxo-1,3-propanediyl]dicarbamate (interm. 42; $[\alpha]_{20}^D = +37.83^\circ$ @ 20.3 mg/2ml in methanol).

b) A solution of intermediate 42 (0.08 mol) and potassium acetate (0.08 mol) in acetic acid (350 ml) was stirred and refluxed for 4 hours. The solvent was evaporated, yielding ethyl (A)-[[2-[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-

10 cyanoethyl]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazin-6-yl]carbonyl]carbamate (interm. 43).

7 c) A solution of intermediate 43 (0.08 mol) in concentrated chloric acid (100 ml) and acetic acid (350 ml) was stirred and refluxed overnight. The reaction mixture was poured out into ice-water, and the resulting precipitate was filtered off, washed with water, then

15 dissolved in CH₂Cl₂/CH₃OH 98/2. The organic solution was dried, filtered and the solvent was evaporated, yielding (A)-2-[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-cyanoethyl]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carboxylic acid (interm. 44; $[\alpha]_{20}^D = +33.76^\circ$ @ 20.38 mg/2ml in methanol).

(B)-2-[3,5-dichloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]-1-cyanoethyl]phenyl]-

20 2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carboxylic acid was prepared in an analogous way (interm. 45).

B. Preparation of the final compounds

Example B.1

A mixture of intermediate 6 (0.044 mol) in mercaptoacetic acid (23ml) was stirred at

25 175°C for 2 hours. The mixture was cooled, poured out on ice, basified with K₂CO₃ and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 99.5/0.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The

30 precipitate was filtered off and dried, yielding 3.7g (17.2%) of (±)-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-α-methylbenzeneacetonitrile (comp. 1.7)

Example B.2

Boron tribromide (0.01932 mol) was added dropwise at -70°C to a solution of intermediate 23 (0.00322 mol) in CH₂Cl₂ (20ml). The mixture was stirred at -70°C for

35 5 hours, then poured out into ice water, basified with K₂CO₃ and extracted with

CH₂Cl₂. The organic layer was separated, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97.5/2.5). The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.30g of (±)-4-chloro-α-[2-chloro-3-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)phenyl]-α-methyl-3-(trifluoromethyl)benzeneacetonitrile (comp. 1.36).

Example B.3

2-methyl-2-propanol, potassium salt (0.0428 mol) was added in one portion at 10°C under N₂ flow to a mixture of 1-[(isocyanomethyl)sulfonyl]-4-methylbenzene (0.0155 mol) in dimethyl sulfoxide (19ml). The mixture was stirred for 10 minutes. Intermediate 29 (0.0119 mol) and methanol (0.9ml) were added. The mixture was stirred at RT for 4 hours, then poured out into water, neutralized with HCl (3N) and extracted with EtOAc. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 99/1). The pure fractions were collected and the solvent was evaporated, yielding 2.39g (46%) of (±)-4-chloro-α-[2-chloro-3-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)phenyl]-3-(trifluoromethyl)-benzeneacetonitrile (comp. 1.38).

Example B.4

A mixture of intermediate 32 (18.4 g) and copper(I)cyanide (6.7 g) was stirred for 30 minutes at 180°C. After cooling, the reaction mixture was taken up in a mixture of CHCl₃/CH₃OH (90:10). The whole was filtered and the filtrate was evaporated. The residue was crystallized from a mixture of CHCl₃/CH₃OH (98:2). The product was filtered off, washed with 2,2'-oxybispropane and dried, yielding 6.7 g (37.3%) of α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl) benzeneacetonitrile; (comp. 1.41; mp. 206.3°C).

Example B.5

A mixture of 2-chloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-α-methylbenzeneacetonitrile (0.01 mol) and triethylamine (0.01 mol) in pyridine (115ml) was heated at 60°C. H₂S was bubbled through the mixture for 5 hours. The mixture was then stirred at 60°C for 16 hours. H₂S was bubbled through the mixture again for 8 hours and the mixture was then stirred at 60°C for 48 hours. H₂S was bubbled through the mixture for 3 days. The solvent was evaporated and the residue was taken up in CH₂Cl₂, washed with an HCl (3N) and with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected

and the solvent was evaporated, yielding 1.5g (36%) of (\pm)-2-chloro- α -(4-chlorophenyl)- α -methyl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)benzeneethanethioamide (comp. 1.21)

Example B.6

- 5 a) Compound 2.8 (0.00474 mol) was added portionwise to H₂SO₄ (5ml), acetic acid (5ml) and H₂O (5ml). The mixture was stirred at 140°C for 14 hours and then poured out into H₂O. The precipitate was filtered off, washed with H₂O, taken up in EtOAc, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was crystallized from EtOAc and diethyl ether. The precipitate was filtered off and dried,
10 yielding 0.7g (33%) of (\pm)-2,6-dichloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α -methylbenzeneacetonitrile (comp. 1.11).
- b) A mixture of 2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α -methylbenzeneacetonitrile (0.026 mol) in H₂SO₄ (75ml), acetic acid (75ml) and H₂O (75ml) was stirred at 140°C for 24 hours. H₂SO₄ (25ml) and acetic acid (25ml)
15 were added again. The mixture was stirred and refluxed for 18 hours and then poured out on ice. The precipitate was filtered off, taken up in EtOAc, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was taken up in CH₂Cl₂, washed with H₂O, dried, filtered and the solvent was evaporated. Part of this residue (1g) was taken up in H₂O and NaOH 3N, treated with activated charcoal, filtered over celite,
20 extracted with CH₂Cl₂ and separated into its layers. The aqueous layer was acidified with HCl 3N and extracted with CH₂Cl₂. The combined organic layer was washed with H₂O, dried, filtered and the solvent was evaporated, yielding 0.56g (\pm)-2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α -methylbenzeneacetic acid (comp. 1.12)

25 Example B.7

- a) A mixture of 2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)benzeneacetic acid (0.0178 mol) in thionyl chloride (30ml) was stirred and refluxed for 2 hours. The mixture was cooled and the solvent was evaporated, yielding 6.5 g of (\pm)-2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)benzeneacetyl chloride (comp. 1.5).
30 b) A mixture of compound 1.56 (0.0038 mol) in thionylchloride (11 ml) was stirred and refluxed for 2 hours. The solvent was evaporated, yielding (\pm)-2,6-dichloro- α -[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-benzeneacetyl chloride (comp. 1.57).

35 Example B.8

A mixture of compound 1.5 (0.0158 mol), *O,N*-dimethylhydroxylamine (0.0237 mol)

and triethylamine (0.0521 mol) in CH_2Cl_2 (150ml) was stirred at RT for 12 hours. The mixture was washed with K_2CO_3 (10%) and with water, dried, filtered and the solvent was evaporated. The residue was taken up in CH_2Cl_2 , washed with HCl (3N) and with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98/2). The pure fractions were collected and the solvent was evaporated. The residue was recrystallized from CH_3CN and diethyl ether. The precipitate was filtered off and dried, yielding 2.15g (34%) of (\pm)-2-chloro- α -(4-chlorophenyl)-*N*-methoxy-*N*-methyl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)benzeneacetamide (comp. 1.6).

10 Example B.9

A solution of (\pm)-2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α -methylbenzeneacetyl chloride (0.007 mol) in CH_2Cl_2 (20ml) was added at RT to methanamine 40% in water (0.105 mol). The mixture was stirred at RT for 4 hours, then poured out into water, acidified with HCl (3N) and extracted with CH_2Cl_2 . The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 97/3). The pure fractions were collected and the solvent was evaporated, yielding 1.25g (43%) of (\pm)-2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α ,*N*-dimethylbenzeneacetamide (comp. 1.14).

20 Example B.10

n-Butyllithium, (1.6M solution in hexane; 0.0575 mol) was added at -70°C under N_2 flow to a solution of benzothiazole (0.0575 mol) in THF (150ml), and the mixture was stirred at -70°C for 30 minutes. Compound 1.6 (0.0115 mol) in THF (100ml) was added dropwise, the mixture was stirred at -70°C for 3 hours, poured out into water and extracted with EtOAc. The organic layer was separated, dried, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1). The pure fractions were collected and the solvent was evaporated. The residue (1.7g) was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 1.35g of (\pm)-2-[4-[2-(2-benzothiazolyl)-1-(4-chlorophenyl)-2-oxoethyl]-3-chlorophenyl]-1,2,4-triazin-3,5(2*H*,4*H*)-dione (comp. 1.20).

30 Example B.11

Acetic acid, ammonium salt (3g) was added at RT to a solution of (\pm)-2-chloro- α -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)- α -methylbenzeneacetyl chloride (0.007 mol) in 2-propanone (30ml). The mixture was stirred at RT for 5 hours. Acetic acid, ammonium salt was filtered off and the solvent was evaporated. The residue was taken up in CH_2Cl_2 , washed with water, dried, filtered and the solvent

was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and the solvent was evaporated, yielding 1.6g (57%) of (±)-2-chloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-α-methylbenzeneacetamide (comp. 1.18).

5 Example B.12

A mixture of compound 1.68 (0.031 mol) in HBr in acetic acid (110ml; 33% solution) and HBr (65ml; 48% aqueous solution) was stirred and refluxed overnight and then poured out into ice water. The precipitate was filtered off, washed with H₂O and taken up in CH₂Cl₂ and a small amount of CH₃OH. The organic solution was dried, filtered and the solvent was evaporated, yielding 13.6g of (±)-2,6-dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-α-methylbenzeneacetic acid; (comp. 1.69).

Example B.13


A mixture of intermediate (41) (0.00457 mol) in concentrated HCl (25ml) and acetic acid (44ml) was stirred and refluxed overnight. The mixture was allowed to cool to RT, poured out on ice, basified with K₂CO₃ and extracted with CH₂Cl₂ and a small amount of CH₃OH. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (2.1g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 90/10/1 and 70/30/1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from EtOAc and 2-propanone. The precipitate was filtered off and dried, yielding 0.95g (45%) of (±)-2-chloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3*H*)-yl)-α-[3-(dimethylamino)propyl]-benzeneacetonitrile; mp. 140°C (Kofler) (comp. 1.58).

Example B.14




















A mixture of compound 1.5 (0.05 mol) in THF (350 ml) was stirred at -75°C. A solution of chloro(phenylmethyl) magnesium (0.1 mol; 2 M/THF) in THF (50 ml) was added dropwise over 1 hour at -75°C. The mixture was stirred at -75°C for 4 hours, then the temperature was raised to -20°C and a saturated NH₄Cl solution (50 ml) was added dropwise over 15 minutes. Water was added and the layers were separated. The organic layer was evaporated. The residue was dissolved in CH₂Cl₂/CH₃OH 90/10. The organic layer was dried, filtered and the solvent was evaporated. The residue was stirred in CH₂Cl₂. The solid was filtered off, the filtrate was evaporated and the residue was filtered over silica gel using a mixture of CH₂Cl₂/CH₃OH 98/2 as eluent. The desired product fraction was collected and the solvent was evaporated, yielding 4.3 g (±)-2-[3-chloro-4-[1-(4-chlorophenyl)-2-oxo-3-phenylpropyl]phenyl]-1,2,4-triazine-3,5(2*H*,4*H*)-dione (comp. 1.67).

Tables 2 to 5 list the compounds of formula (I) which were prepared according to one of the above examples (column "Ex. No.")

Table 2




Comp. No.	Ex. No.	R ¹	R ²	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4c}	R ^{4d}
1.1	B.1	CH ₃	CN	H	H	Cl	H	H
1.2	B.5	H		H	H	H	H	H
1.3	B.1	CH ₃	CN	H	H	OCH ₃	H	H
1.4	B.1	CH ₃	CN	H	CH ₃	CF ₃	H	H
1.5	B.7a	H		H	H	H	H	H
1.6	B.8	H		H	H	H	H	H
1.7	B.1	CH ₃	CN	Cl	H	CF ₃	H	H
1.8	B.8	H		Cl	H	H	H	H
1.9	B.1	CH ₃	CN	Cl	H	Cl	H	H
1.10	B.9	H		H	H	H	H	H
1.11	B.6a	CH ₃		Cl	H	H	H	H
1.12	B.6b	CH ₃		H	H	H	H	H
1.13	B.7a	CH ₃		H	H	H	H	H
1.14	B.9	CH ₃		H	H	H	H	H
1.15	B.10	H		H	H	H	H	H
1.16	B.5	CH ₃		Cl	H	H	H	H
1.17	B.1	CH ₃	CN	H	H	CH ₃	H	H
1.18	B.11	CH ₃		H	H	H	H	H
1.19	B.1	CH ₃	CN	H	H	H	H	Cl

Comp. No.	Ex. No.	R ¹	R ²	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4c}	R ^{4d}
1.20	B.10	H		H	H	H	H	H
1.21	B.5	CH ₃		H	H	H	H	H
1.22	B.10	H		H	H	H	H	H
1.23	B.8	CH ₃		H	H	H	H	H
1.24	B.9	CH ₃		H	H	H	H	H
1.25	B.10	H		Cl	H	H	H	H
1.26	B.5	CH ₃		Cl	H	CF ₃	H	H
1.27	B.5	H		Cl	H	CF ₃	H	H
1.28	B.5	CH ₃		Cl	H	Cl	H	H
1.29	B.5	CH ₃		H	CH ₃	CF ₃	H	H
1.30	B.10	H		H	H	H	H	H
1.31	B.5	CH ₃		H	H	CF ₃	H	H
1.32	B.6b	CH ₃		H	H	CF ₃	H	H
1.33	B.7a	CH ₃		H	H	CF ₃	H	H
1.34	B.6b			H	H	H	H	H
1.53	B.1	CH ₃	CN	Cl	H	CF ₃	H	H
1.54	B.1	CH ₃	CN	Cl	H	CF ₃	H	H
1.55	B.5	CH ₃		H	H	CH ₃	H	H
1.56	B.6b	H		Cl	H	CF ₃	H	H
1.57	B.7b	H		Cl	H	CF ₃	H	H
1.58	B.13	(CH ₂) ₃ -N(CH ₃) ₂	CN	H	H	H	H	H
1.59	B.1	H	CN	Cl	H	CH ₃	H	H


Comp. No.	Ex. No.	R ¹	R ²	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4c}	R ^{4d}
1.60	B.5	H		Cl	H	CH ₃	H	H
1.61	B.14	H		Cl	H	H	H	H
1.62	B.14	H		Cl	H	H	H	H
1.63	B.1	CH ₃	CN	Cl	H	F	H	H
1.64	B.5	CH ₃		Cl	H	F	H	H
1.65	B.1	H	CN	Cl	H	CH ₃ O	H	H
1.66	B.5	H		Cl	H	CH ₃ O	H	H
1.67	B.14	H		H	H	H	H	H
1.68	B.1	CH ₃		Cl	H	H	H	H
1.69	B.12	CH ₃		Cl	H	H	H	H
1.70	B.7a	CH ₃		Cl	H	H	H	H

Table 3




Comp. No.	Ex. No.	R ¹	R ^{3a}	R ^{3b}
1.35	B.2	CH ₃	H	Cl
1.36	B.2	CH ₃	Cl	H
1.37	B.3	H	H	Cl
1.38	B.3	H	Cl	H

Table 4



Comp. No.	Ex. No.	R ¹	R ^{3a}	R ^{3b}	R ^{4a}	R ^{4b}	R ^{4c}	R ^{4d}
1.39	B.1	H	Cl	Cl	H	H	H	H
1.40	B.1	H	Cl	Cl	H	OCH ₃	H	H
1.41	B.4	H	H	H	H	Cl	H	H
1.42	B.1	CH ₃	Cl	H	OCH ₃	OCH ₃	H	H
1.43	B.1	CH ₃	Cl	H	H	OCH ₃	H	H
1.44	B.1	CH ₃	Cl	H	Cl	OCH ₃	H	H
1.45	B.1	CH ₃	OCH ₃	H	CF ₃	Cl	H	H
1.46	B.1	CH ₃	Cl	H	OCH ₃	OCH ₃	OCH ₃	H
1.47	B.1	CH ₃	Cl	H	CH ₃	OCH ₃	H	H
1.48	B.1	CH ₃	H	H	H	Cl	H	Cl
1.49	B.1	CH ₃	CH ₃	H	CF ₃	Cl	H	H
1.50	B.1	CH ₃	Cl	H	H	phenyl	H	H
1.51	B.1	H	Cl	Cl	CF ₃	Cl	H	H
1.52	B.2		Cl	H	H	Cl	H	H
1.71	B.1	H	CH ₃	CH ₃	Cl	Cl	H	H
1.72	B.1	H	Br	Br	H	Cl	H	H

Table 5



Comp. No.	Ex. No.	R ¹	R ^{3a}	R ^{3b}	R ^{4a}
1.73	B.5	CH ₃	CH ₃ O	H	CF ₃
1.74	B.5	H	CH ₃	CH ₃	Cl
1.75	B.5	H	Br	Br	H

Table 6 lists both the experimental (column heading "Exp") and theoretical (column heading "Theor") elemental analysis values for carbon (C), hydrogen (H) and nitrogen (N) for the compounds as prepared in the experimental part hereinabove.

Table 6

Comp. No.	C		H		N	
	Theor	Exp	Theor	Exp	Theor	Exp
1.1	51.27	51.28	2.63	2.21	13.29	13.06
1.2	50.13	49.72	2.97	2.62	13.76	12.95
1.3	54.69	54.04	3.38	3.44	13.43	12.96
1.4	51.19	51.3	2.79	2.71	11.94	11.75
1.6	52.43	52.25	3.71	3.89	12.87	12.69
1.7	46.60	46.8	2.06	2.00	11.44	11.3
1.8	48.59	48.22	3.22	2.90	11.93	11.45
1.9	47.40	47.25	2.21	2.22	12.28	11.95
1.11	49.17	49.47	2.98	3.11	12.74	11.92
1.12	53.22	51.73	3.23	3.17	10.34	9.88
1.14	54.43	53.2	3.85	3.88	13.36	12.85
1.15	55.28	54.18	3.31	3.39	15.35	14.83
1.17	56.87	56.33	3.52	3.46	13.96	13.43
1.18	53.35	51.78	3.48	3.53	13.83	13.17
1.19	51.27	51.38	2.63	2.67	13.29	13.15
1.20	56.59	56.45	2.77	2.66	11	10.77
1.21	51.32	49.63	3.35	3.35	13.3	12.62
1.22	52.3	54.18	2.63	2.9	12.2	11.54
1.23	53.47	52.5	4.04	3.93	12.47	12.14
1.25	51.4	51.48	2.88	2.98	14.27	13.91
1.30	58.33	58.25	3.01	3.04	10.46	10.27
1.35	50.13	50.21	2.44	2.35	12.31	12.12
1.36	50.13	50.19	2.44	2.51	12.31	11.79
1.37	49	49.34	2.06	1.88	12.7	12.45
1.42	58.19	58.31	4.15	4.23	13.57	13.44
1.43	59.61	57.79	3.95	3.87	14.64	14.19
1.44	54.69	54.78	3.38	3.46	13.43	13.06
1.45	53.29	53.3	3.13	3.08	12.43	12.14
1.46	56.96	56.13	4.32	4.13	12.65	12.4
1.47	60.53	60.78	4.32	4.41	14.12	13.63
1.48	55.83	55.83	3.12	3.08	14.47	14.30
1.49	55.25	55.36	3.25	3.21	12.89	12.90
1.50	67.21	65.87	4.00	4.13	13.06	12.68
1.52	59.35	59.39	3.14	3.04	12.82	12.63
1.53	46.60	46.62	2.06	1.95	11.44	11.37
1.54	46.60	46.51	2.06	1.96	11.44	11.44
1.58	57.65	56.55	4.62	4.65	15.28	14.12
1.61	57.56	57.62	3.22	3.22	8.39	8.45
1.71	56.87	56.69	3.52	3.58	13.96	13.41


C. Pharmacological exampleExample C.1 : *in vitro* inhibition of IL-5 production in human bloodHuman whole blood stimulation

Peripheral blood from healthy male donors was drawn into heparinized syringes (12.5 U heparin/ml). Blood samples were three-fold diluted in RPMI 1640 medium (Life Technologies, Belgium) supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, and 300 µl fractions were distributed in 24-well multidisc plates. Blood samples were preincubated (60 minutes at 37°C) in a humidified 6% CO₂-atmosphere with 100 µl of drug solvent (final concentration 0.02% dimethylsulfoxide in RPMI 1640) or with 100 µl of an appropriate dose of test compound before being stimulated by the addition of 100 µl of phytohemagglutinin HA17 (Murex, UK) at a final concentration of 2 µg/ml. After 48 hours, cell-free supernatant fluids were collected by centrifugation and stored at -70°C until tested for the presence of IL-5.

15 IL-5 measurements

IL-5 measurements were conducted as described in Van Wauwe et al. (1996, *Inflamm Res*, 45, 357-363) on page 358 using ELISA.

Table 8 lists the percentage inhibition of IL-5 production (column "% inhibition") at a test dose of 1×10^{-6} M, or in case the percentage inhibition is marked with an "*" 1×10^{-5} M, for the compounds of the present invention including compounds of formula (I) which have been disclosed in US 4,631,278 (Ref. A) or US 4,767,760 (Ref. B) as summarized in table 7.

Table 7

25

Co. No.	Ref	R ¹	R ²	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}
2.1	A	CH ₃	CN	H	H	H	H	H
2.2	A	CH ₃	CN	Cl	H	H	H	F
2.3	A	CH ₃	CN	CF ₃	H	H	H	Cl
2.4	A	4-chlorophenyl	CN	Cl	H	H	H	Cl
2.5	A	(CH ₂) ₂ -CH ₃	CN	Cl	H	H	H	Cl
2.6	A	(CH ₂) ₃ -CH ₃	CN	Cl	H	H	H	Cl
2.7	A	CH ₃	CN	Cl	H	H	CF ₃	Cl


Co. No.	Ref	R ¹	R ²	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}
2.8	A	CH ₃	CN	Cl	Cl	H	H	Cl
2.9	A	H	CN	Cl	H	H	H	Cl
2.10	A	CH ₃	CN	Cl	CH ₃	H	H	Cl
2.11	A	CH ₃	CN	Cl	H	CH ₃	H	Cl
2.12	A	H	CN	Cl	Cl	H	H	Cl
2.13	A	H	CN	Cl	H	H	H	F
2.14	A	H	CN	Cl	H	H	H	CH ₃
2.15	A	CH ₃	CN	F	H	H	H	F
2.16	A	H	CN	Cl	Cl	H	H	F
2.17	A	H	CN	Cl	CH ₃	H	H	F
2.18	A	H	CN	CH ₃	CH ₃	H	H	F
2.19	A	H	CN	CH ₃	CH ₃	H	H	Cl
2.20	B	H	C(=O)NHCH ₃	Cl	Cl	H	H	Cl
2.21	B	H		Cl	Cl	H	H	Cl
2.22	B	H	C(=O)CH ₃	Cl	Cl	H	H	Cl
2.23	B	H	C(=S)NH ₂	Cl	Cl	H	H	Cl

Table 8

Co. No.	% inhibition
1.1	63
1.2	11
1.3	40
1.4	87
1.6	49
1.7	92
1.8	42
1.9	84
1.11	12
1.14	9
1.15	70
1.17	63
1.19	49
1.20	80
1.21	33
1.23	62
1.24	12
1.25	6
1.35	33
1.36	44

Co. No.	% inhibition
1.37	12
1.39	31
1.41	13
1.42	22
1.43	5
1.44	46
1.45	41
1.46	33
1.47	38
1.48	2
1.49	69
1.50	24
1.53	95
1.54	95
1.58	28
1.61	72
1.71	23
2.1	14
2.2	22
2.3	37

Co. No.	% inhibition
2.4	16
2.5	67
2.6	81
2.7	85
2.8	87
2.9	21
2.10	81
2.11	53
2.12	37
2.13	48*
2.14	37
2.15	14
2.16	10
2.17	23
2.18	9
2.19	20
2.20	31
2.21	25
2.22	83
2.23	47

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to animal and human subjects in accordance with the present invention.

- 5 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable addition salt thereof.

Example D.1 : film-coated tabletsPreparation of tablet core

- 10 A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and thereafter humidified with a solution of sodium dodecyl sulfate (5 g) and polyvinyl-pyrrolidone (10 g) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

15 Coating


- To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in dichloromethane (150 ml). Then there were added dichloromethane (75 ml) and 1,2,3-propanetriol (2.5 ml). Polyethylene glycol (10 g) was molten and dissolved in dichloromethane (75 ml). The latter solution was added to the
20 former and then there were added magnesium octadecanoate (2.5 g), polyvinyl-pyrrolidone (5 g) and concentrated color suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example D.2 : 2% topical cream

- 25 To a solution of hydroxypropyl β -cyclodextrine (200 mg) in purified water is added A.I. (20 mg) while stirring. Hydrochloric acid is added until complete dissolution and next sodium hydroxide is added until pH 6.0. While stirring, glycerol (50 mg) and polysorbate 60 (35 mg) are added and the mixture is heated to 70°C. The resulting mixture is added to a mixture of mineral oil (100 mg), stearyl alcohol (20 mg), cetyl alcohol (20 mg), glycerol monostearate (20 mg) and sorbate 60 (15 mg) having a
30 temperature of 70°C while mixing slowly. After cooling down to below 25°C, the rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.

Claims

1. The use of a compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, 2, 3 or 4;

q represents an integer being 0, 1, 2, 3, 4 or 5;

*R*¹ represents hydrogen, C₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxy, mercapto, C₁₋₆alkylthio, C₃₋₇cycloalkyl, aryl or C₁₋₆alkyl substituted with mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxy, aryl or Het;

*R*² represents cyano or a radical of formula -C(=X)-Y-R⁵; wherein

X represents O or S;

Y represents O, S, NR⁶ or a direct bond;

*R*⁵ represents hydrogen; C₁₋₆alkyl; C₃₋₇cycloalkyl; aryl or C₁₋₆alkyl substituted with aryl, hydroxy or Het; and where *Y* is a direct bond, *R*⁵ may also be halo or Het;

*R*⁶ represents hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or arylC₁₋₆alkyl;


each *R*³ independently represents halo, haloC₁₋₆alkyl, C₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy, mercapto, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfinyl, haloC₁₋₆alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁₋₆alkyl)amino or (C₁₋₆alkylcarbonyl)amino;

each *R*⁴ independently represents halo, haloC₁₋₆alkyl, C₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy, mercapto, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfinyl, haloC₁₋₆alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁₋₆alkyl)amino or (C₁₋₆alkylcarbonyl)amino;


aryl represents phenyl or phenyl substituted with one, two or three substituents selected from the group comprising halo, C₁₋₆alkyl, C₁₋₆alkyloxy, haloC₁₋₆alkyl, hydroxy, mercapto, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonyloxy, C₁₋₆alkylsulfinyl, haloC₁₋₆alkylsulfonyl, nitro, cyano, amino, mono- and di(C₁₋₆alkyl)amino and C₁₋₆alkylcarbonylamino; and

Het represents a heterocycle selected from pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, pyrazolyl, pyrazolynyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolynyl, isoxazolyl,

- thiazolyl, thiazoliny, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzthiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl and thiazolopyridinyl; said heterocycles each independently may be substituted with one, two or three substituents selected from hydroxy, mercapto, C₁₋₄alkyl, C₁₋₄alkyloxy, cyano, amino, nitro, mono- or di(C₁₋₄alkyl)amino, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(aryl)amino, halo, haloC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, aryl, furanyl, thienyl, pyridinyl, piperidinyl, C₁₋₄alkylcarbonylpiperidinyl and C₁₋₄alkyl substituted with hydroxy, C₁₋₄alkyloxy, aryl, piperidinyl, amino, mono- or di(C₁₋₄alkyl)amino or C₃₋₇cycloalkyl;
- in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases.
2. The use of a compound according to claim 1 wherein the eosinophil-dependent inflammatory disease is bronchial asthma.
 3. The use of a compound according to claim 1 wherein the eosinophil-dependent inflammatory disease is atopic dermatitis.
 4. The use of a compound according to claim 1 wherein the eosinophil-dependent inflammatory disease is allergic rhinitis.
 5. The use of a compound according to claim 1 wherein the eosinophil-dependent inflammatory disease is allergic conjunctivitis.
-
6. The use of a compound according to any one of claims 1 to 5 wherein the 6-azauracil moiety is in the para position relative to the central chiral carbon atom; p is 1 or 2 and one R³ substituent is chloro positioned ortho relative to the central chiral carbon atom; q is 1 or 2 and one R⁴ substituent is chloro in the 4 position.
 7. A compound of formula



- a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein p , q , R^1 , R^2 , R^3 and R^4 are as defined in claim 1, provided that the following conditions apply to the variables R^{3a} , R^{3b} , R^{3c} , R^{4a} , R^{4b} , R^{4c} , R^1 and R^2 in the compounds with general structure :



- a) if R^{3a} , R^{3b} are chloro; R^{4a} is 4-chloro; and R^1 , R^{3c} , R^{4b} and R^{4c} are hydrogen; then R^2 is other than aminocarbonyl, carboxyl, chlorocarbonyl, 1-piperidinylcarbonyl, methoxycarbonyl, methylaminocarbonyl, 1-pyrrolidinylcarbonyl, 4-methyl-1-piperazinylcarbonyl, methylcarbonyl, $\text{NH}_2\text{-C(=S)-}$, phenylcarbonyl; and
- b) if R^{3a} is chloro; R^{4a} is 4-chloro; and R^1 , R^{3b} , R^{3c} , R^{4b} and R^{4c} are hydrogen; then R^2 is other than aminocarbonyl, carboxyl, $\text{NH}_2\text{-C(=S)-}$, chlorocarbonyl, methylaminocarbonyl, (4-methylcarbonyl-1-piperazinyl)carbonyl, (4-phenylmethyl-1-piperazinyl)carbonyl or methyloxycarbonyl; and
- c) if the combination of R^1 , R^{3a} , R^{3b} , R^{3c} , R^{4a} , R^{4b} and R^{4c} is one of the following :


R^1	R^{3a}	R^{3b}	R^{3c}	R^{4a}	R^{4b}	R^{4c}
4-chlorophenyl	Cl	H	H	H	4-Cl	H
1-propyl	Cl	H	H	H	4-Cl	H
1-butyl	Cl	H	H	H	4-Cl	H
CH_3	Cl	H	H	H	4-Cl	H
CH_3	H	H	H	H	4-H	H
CH_3	H	Cl	H	H	4-F	H
CH_3	CF_3	H	H	H	4-Cl	H
CH_3	Cl	H	H	3- CF_3	4-Cl	H
CH_3	Cl	Cl	H	H	4-Cl	H
CH_3	Cl	CH_3	H	H	4-Cl	H
CH_3	F	H	H	H	4-F	H
H	Cl	CH_3	H	H	4-Cl	H
H	Cl	H	H	H	4-F	H

R ¹	R ^{3a}	R ^{3b}	R ^{3c}	R ^{4a}	R ^{4b}	R ^{4c}
H	Cl	H	H	H	4-CH ₃	H
H	Cl	Cl	H	H	4-F	H
H	Cl	CH ₃	H	H	4-F	H
H	CH ₃	CH ₃	H	H	4-F	H
H	CH ₃	CH ₃	H	H	4-Cl	H
H	Cl	Cl	H	H	4-Cl	H
H	Cl	H	H	H	4-Cl	H
H	Cl	H	H	2-Cl	4-Cl	H
H	Cl	H	H	2-Cl	4-Cl	6-Cl
H	Cl	H	H	H	4-Br	H
H	Cl	Cl	H	H	4-Br	H
H	Cl	Cl	H	H	4-CH ₃ C(=O)O	H
H	Cl	Cl	H	H	4-OH	H
H	OH	H	H	H	4-Cl	H
H	Cl	H	H	H	4-CH ₃ S	H
H	Cl	Cl	H	H	4-CH ₃ S	H
H	CH ₃	CH ₃	H	H	4-CH ₃ S	H
H	Cl	H	H	3-CH ₃	4-CH ₃ S	H
H	Cl	Cl	H	3-CH ₃	4-CH ₃ S	H
H	Cl	H	H	H	4-CH ₃ SO	H
H	Cl	Cl	H	H	4-CH ₃ SO	H
H	Cl	H	H	H	4-CH ₃ S(O) ₂	H
H	Cl	Cl	H	H	4-CH ₃ S(O) ₂	H
H	Cl	H	H	H	4-SH	H
H	Cl	Cl	H	H	4-SH	H
CH ₃	Cl	H	CH ₃	4-Cl	H	H
H	H	H	OCH ₃	4-Cl	H	H


then R² is other than cyano.

8. A compound as claimed in claim 7 wherein R² is cyano or a radical of formula
 $-C(=X)-Y-R^5$ wherein R⁵ is hydrogen, C₁₋₆alkyl or aryl while Y is O, S or NR⁶
 wherein R⁶ is hydrogen or C₁₋₆alkyloxy; or R⁵ is aryl, C₁₋₆alkyl, halo, Het or
 C₁₋₆alkyl substituted with aryl while Y is a direct bond.
9. A compound as claimed in claim 7 or 8 wherein R³ and R⁴ each independently are
 halo, haloC₁₋₆alkyl, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy or aryl.


10. A compound as claimed in any one of claims 7 to 9 wherein the 6-azauracil moiety is in the para position relative to the central chiral carbon atom; p is 1 or 2 and one R^3 substituent is chloro positioned ortho relative to the central chiral carbon atom; q is 1 or 2 and one R^4 substituent is chloro in the 4 position.
11. A compound as claimed in claim 7 wherein R^2 is a radical of formula $-C(=X)-Y-R^5$ wherein Y is a direct bond and R^5 is Het.
12. A compound as claimed in claim 7 wherein R^1 is mono-or di(C_{1-6} alkyl)amino C_{1-6} alkyloxy, mercapto, C_{1-6} alkylthio or C_{1-6} alkyl substituted with mono-or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxy or Het.
13. A process for preparing a compound of formula (I') as claimed in claim 7, characterized by,
- a) cyclizing an intermediate of formula (II) and eliminating the group E from the thus obtained dione of formula (III);




- b) eliminating the group P in the intermediates of formula (IV);



- c) converting the function of an intermediate of formula (V) into a suitable leaving group W such as, for example, a halogen or a sulfonyloxy group, and subsequently converting said leaving group W in the thus formed intermediate of formula (VI) into a nitrile function; thus forming a compound of formula (I'-a);



d) reacting the group in an intermediate of formula (VII) with a suitable reagent 1-[(isocyanomethyl)sulfonyl]-4-methylbenzene or a functional derivative thereof;



5

e) converting compounds of formula (I') into each other following art-known transformations, and further, if desired, converting the compounds of formula (I'), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

10

14. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 11 or 12.

15. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound of formula (I) as defined in claim 1 together with instructions for the use thereof for the treatment of an eosinophil-dependent inflammatory disease.

20

16. A compound as claimed in claim 11 or 12 for use as a medicine.
17. A process of marking a receptor comprising the steps of
- a) radiolabelling a compound as defined in claim 1;
 - 5 b) administering said radiolabelled compound to biological material,
 - c) detecting the emissions from the radiolabelled compound.
18. A process of imaging an organ, characterized by, administering a sufficient
- 10 amount of a radiolabelled compound of formula (I) in an appropriate composition, and detecting the emissions from the radioactive compound.

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/EP 98/04192

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D253/06 A61K31/53 C07D403/10 C07D417/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 767 760 A (BOECKX GUSTAAF M ET AL) 30 August 1988 cited in the application see column 3; the compounds of formula (II) see column 7, line 47 - column 8, line 11 see column 14, line 44 - line 60	7-10, 13, 15
X	US 4 631 278 A (BOECKX GUSTAAF M ET AL) 23 December 1986 cited in the application see column 1, line 32 - line 57 see column 5, line 46 - line 59 see column 2, line 26 - line 61	7-10, 13, 15
X	EP 0 476 439 A (BAYER AG) 25 March 1992 see page 25 - page 30; claims 1, 2, 4, 6, 9, 10 -/-	7-10, 13, 15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

21 October 1998

Date of mailing of the international search report

28/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

Int'l. Application No

PCT/EP 98/04192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 737 672 A (TAKEDA CHEMICAL INDUSTRIES LTD) 16 October 1996 see page 27; claim 14 see page 25, line 31 - line 35 ----	7-10, 15
A	WO 96 31485 A (JANSSEN PHARMACEUTICA NV ;FREYNE EDDY JEAN EDGARD (BE); DIELS GAST) 10 October 1996 see page 50 - page 51; claim 1 ----	1-18
A	US 4 931 444 A (VAN WAUWE JEAN P F ET AL) 5 June 1990 see column 40 - column 42; claim 1 see column 35; table 10, the compounds 10.01 - 10.07 ----	1-18
A	WO 94 20446 A (CELLTECH LTD) 15 September 1994 see page 40; claim 1 see page 2, line 6 - line 19 ----	1-18
A	WO 94 14742 A (CELLTECH LTD) 7 July 1994 see page 98; claim 1 see page 2, line 6 - line 19 -----	1-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. J. Appl. Application No

PCT/EP 98/04192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4767760 A	30-08-1988	AU 586731 B	20-07-1989
		AU 6813487 A	06-08-1987
		CA 1288772 A	10-09-1991
		CA 1302411 A	02-06-1992
		CN 1017049 B	17-06-1992
		DK 48187 A	31-07-1987
		DK 65193 A	04-06-1993
		EP 0232932 A	19-08-1987
		FI 870421 A,B,	31-07-1987
		FI 923914 A	01-09-1992
		GR 3001392 T	11-09-1992
		IE 59510 B	09-03-1994
		JP 2098097 C	02-10-1996
		JP 8013806 B	14-02-1996
		JP 62190174 A	20-08-1987
		JP 2622510 B	18-06-1997
		JP 7285949 A	31-10-1995
		NO 175056 B	16-05-1994
		PT 84218 B	31-07-1989
		RU 2017736 C	15-08-1994
		SU 1595339 A	23-09-1990
		US 4912106 A	27-03-1990
		US 4952570 A	28-08-1990
US 4631278 A	23-12-1986	MX 174156 B	25-04-1994
		AU 579653 B	01-12-1988
		AU 4566485 A	06-02-1986
		BG 46599 A	15-01-1990
		CA 1244024 A	01-11-1988
		CA 1305479 A	21-07-1992
		CY 1656 A	14-05-1993
		DK 347585 A	02-02-1986
		EG 17589 A	30-12-1991
		EP 0170316 A	05-02-1986
		FI 852958 A,B	02-02-1986
		GR 851837 A	02-12-1985
		HK 68092 A	18-09-1992
		IE 58076 B	30-06-1993
		JP 1732518 C	17-02-1993
		JP 4020435 B	02-04-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. J. Appl. No.

PCT/EP 98/04192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4631278	A		JP 61043176 A	01-03-1986
			JP 1901539 C	27-01-1995
			JP 5017454 A	26-01-1993
			JP 6025177 B	06-04-1994
			LT 37093 R	15-06-1993
			LV 5027 A	10-06-1993
			PT 80903 B	11-11-1987
			SK 557685 A	04-09-1996
			SU 1443799 A	07-12-1988
			US 4778887 A	18-10-1988
EP 0476439	A	25-03-1992	DE 4029534 A	19-03-1992
			DE 4120138 A	24-12-1992
			AU 639825 B	05-08-1993
			AU 8388691 A	26-03-1992
			CA 2051323 A	19-03-1992
			EG 19767 A	31-01-1996
			JP 5001047 A	08-01-1993
			US 5256631 A	26-10-1993
EP 0737672	A	16-10-1996	CA 2174063 A	15-10-1996
			CN 1140712 A	22-01-1997
			JP 8337576 A	24-12-1996
WO 9631485	A	10-10-1996	AU 5275596 A	23-10-1996
			CA 2216653 A	10-10-1996
			CN 1181072 A	06-05-1998
			EP 0819122 A	21-01-1998
			HR 960155 A	31-10-1997
			NO 974602 A	06-10-1997
			PL 322654 A	16-02-1998
US 4931444	A	05-06-1990	AT 105711 T	15-06-1994
			AU 3073989 A	31-08-1989
			BG 49940 A	16-03-1992
			CA 1331757 A	30-08-1994
			CN 1036569 A,B	25-10-1989
			DE 68915308 D	23-06-1994
			DE 68915308 T	06-10-1994
			DK 91889 A	30-08-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 98/04192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4931444 A		EP 0331232 A	06-09-1989
		ES 2056190 T	01-10-1994
		FI 890931 A, B,	30-08-1989
		HU 68931 A	28-08-1995
		IE 63150 B	22-03-1995
		JP 1975128 C	27-09-1995
		JP 2003678 A	09-01-1990
		JP 7005564 B	25-01-1995
		NO 174049 C	09-03-1994
		PH 26574 A	19-08-1992
		PT 89875 A, B	04-10-1989
WO 9420446 A	15-09-1994	AU 675511 B	06-02-1997
		AU 6148994 A	26-09-1994
		CA 2135480 A	15-09-1994
		EP 0640065 A	01-03-1995
		JP 8505158 T	04-06-1996
		NZ 262170 A	24-02-1997
		US 5739144 A	14-04-1998
WO 9414742 A	07-07-1994	AU 680224 B	24-07-1997
		AU 5709294 A	19-07-1994
		CA 2129039 A	07-07-1994
		CN 1092064 A	14-09-1994
		CZ 9402034 A	15-12-1994
		EP 0626939 A	07-12-1994
		FI 943856 A	22-08-1994
		GB 2279075 A, B	21-12-1994
		HU 70559 A	30-10-1995
		HU 9500330 A	30-10-1995
		JP 7504442 T	18-05-1995
		MX 9400175 A	29-07-1994
		NO 943091 A	21-10-1994
		NZ 258982 A	24-02-1997
		PL 304892 A	09-01-1995
		US 5622977 A	22-04-1997
		ZA 9309623 A	18-08-1994